J. Gallant

发表

Loss of HIV-1-specific immunity during treatment interruption in 2 chronically infected patients.

R. Siliciano, J. Bartlett, J. Blankson, 2002, JAMA.

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

J. Lisziewicz, E. Rosenberg, R. Siliciano, 1999, Nature Medicine.

Protease-inhibitor boosting in the treatment-experienced patient.

J. Gallant, 2004, AIDS reviews.

Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.

Tara L. Kieffer, R. Siliciano, J. Gallant, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Erratum: Marked intraindividual variability in antiretrovrial concentrations may limit the utility of therapeutic drug monitoring (Clinical Infectious Diseases (April 15, 2006) 42 (1189-1196))

Tara L. Kieffer, R. Siliciano, J. Gallant, 2006 .

Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America.

V. Stone, J. Gallant, J. Currier, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

Jack T Stapleton, Stuart Haber, David Heckerman, 2010, Science.

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

R Brookmeyer, R. Siliciano, J. Margolick, 1997, Science.

Making sense of blips.

J. Gallant, 2007, The Journal of infectious diseases.

Initial regimens for the treatment-naive patient: current understanding and practice.

J. Gallant, C. Hoffmann, 2008, The AIDS reader.

Should antiretroviral therapy be started earlier?

J. Gallant, 2007, Current HIV/AIDS reports.

Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study.

J. Gallant, S. Staszewski, J. Hulot, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Prophylaxis for Opportunistic Infections in Patients with HIV Infection

R. Chaisson, J. Gallant, R. Moore, 1994, Annals of Internal Medicine.

Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes

J. Gallant, P. Karakousis, J. Mitty, 2007, Journal of Translational Medicine.

Renal function with use of a tenofovir-containing initial antiretroviral regimen

Richard D Moore, J. Gallant, Richard D. Moore, 2009, AIDS.

Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment.

Richard D Moore, J. Gallant, J. Keruly, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral therapy in the treatment of HIV-associated nephropathy.

D. Fine, J. Gallant, P. Scheel, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients

J. Gallant, A. Pozniak, Shan-Shan Chen, 2008, AIDS.

Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients.

R. Chaisson, J. Gallant, J. Keruly, 1996, The Journal of infectious diseases.

Tenofovir, Equivalence, and Noninferiority—Reply

J. Gallant, S. Staszewski, A. Pozniak, 2004 .

Risk factors for human herpesvirus 8 seropositivity in the AIDS Cancer Cohort Study.

J. Goedert, J. Gallant, D. Whitby, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis

J. Gallant, A. Lok, N. Terrault, 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

A Systematic Review of HIV/AIDS Survival and Delayed Diagnosis Among Hispanics in the United States

J. Gallant, K. Page, Nadine E. Chen, 2012, Journal of Immigrant and Minority Health.

Risk Factors for Kaposi's Sarcoma in Patients With Advanced Human Immunodeficiency Virus Disease Treated With Zidovudine

Richard D Moore, R. Chaisson, D. Richman, 1994 .

Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.

R. Chaisson, D. Richman, J. Gallant, 1992, The Journal of infectious diseases.

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.

D. Ward, J. Gallant, M. Johnson, 2016, The lancet. HIV.

Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings?

J. Gallant, J. Sugarman, S. Mehta, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

F. Antunes, J. Gallant, J. Fehr, 2013, The Journal of infectious diseases.

Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults

R. Chaisson, J. Nachega, J. Gallant, 2008, AIDS.

Psychological Distress and Physical Pain Appear To Have No Short-Term Adverse Impact on Plasma HIV-1 RNA Levels in Patients on Successful HAART

Tara L. Kieffer, R. Siliciano, A. Wu, 2005, HIV clinical trials.

Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia

D. Havlir, A. Zolopa, J. Gallant, 2002, Antimicrobial Agents and Chemotherapy.

Reply to Gupta

Richard D Moore, J. Gallant, J. Keruly, 2005 .

Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.

Joel E Gallant, David D Celentano, Stephen J Gange, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia.

R. Chaisson, J. Bartlett, J. Gallant, 1995, Chest.

High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I

K. White, P. Sax, J. Gallant, 2022, AIDS.

Antiretroviral Therapy for the Prevention of HIV-1 Transmission.

J. Gallant, S. Swindells, I. Hoffman, 2016, The New England journal of medicine.

Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease.

R. Chaisson, J. Gallant, E. Erbelding, 1997, Antiviral therapy.

Lack of Association between Acyclovir Use and Survival in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine

Richard D Moore, R. Chaisson, D. Richman, 1995 .

HIV counseling, testing, and referral.

J. Gallant, 2004, American family physician.

Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy.

J. Perfect, M. Ghannoum, J. Gallant, 1999, AIDS research and human retroviruses.

The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults.

P. Volberding, J. Gallant, M. Saag, 2002, AIDS research and human retroviruses.

Prevention of HIV-1 infection with early antiretroviral therapy.

Lei Wang, David Burns, Kenneth H Mayer, 2011, The New England journal of medicine.

Virologic outcomes in early antiretroviral treatment: HPTN 052

J. Gallant, Myron S. Cohen, K. Mayer, 2017, HIV clinical trials.

HIV Infection: Still a Disease for Experts.

J. Gallant, 2015, Clinical Infectious Diseases.

Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions.

M. Levenstein, J. Gallant, A. Tunkel, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Raltegravir-induced cerebellar ataxia.

J. Gallant, K. Reiss, P. Pham, 2010, AIDS.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Stavudine in zidovudine (ZDV)-experienced compared with ZDV-naive patients.

R. Chaisson, J. Gallant, J. Keruly, 1999, AIDS (London).

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults

J. Gallant, M. Das, S. Oka, 2016, Journal of Acquired Immune Deficiency Syndromes.

Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial

J. Gallant, Myron S. Cohen, K. Mayer, 2016, Journal of acquired immune deficiency syndromes.

Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology.

J. Gallant, J. Keruly, R. Moore, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults

K. White, J. Gallant, A. Cheng, 2017, Journal of acquired immune deficiency syndromes.

Tipranavir.

J. Gallant, 2020, Drugs.

A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk

J. Gallant, C. Hendrix, J. Jackson, 2003, AIDS.

Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use.

J. Gallant, V. Soriano, P. Barreiro, 2002, AIDS reviews.

Efficacy of Nelfinavir in Patients Switched from Ritonavir/Saquinavir Combination Antiretroviral Therapy

J. Gallant, J. Gathe, P. Keiser, 2000, HIV clinical trials.

Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.

O. Laeyendecker, J. Gallant, T. Quinn, 2012, AIDS research and human retroviruses.

Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients

Richard D Moore, J. Bartlett, J. Gallant, 2011, PloS one.

Article Commentary: Dolutegravir Monotherapy: When Should Clinical Practice be Clinical Research?

J. Gallant, J. Sugarman, 2016, Antiviral therapy.

Eff ects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection : results from the phase 3 HPTN 052 randomised controlled trial

D. Havlir, J. Gallant, S. Swindells, 2014 .

Topics in Primary Care Medicine Prophylaxis Against Opportunistic Infections in Patients Infected With the Human Immunodeficiency Virus

R. Chaisson, J. Gallant, L. Cheever, 2005 .

Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2021, The lancet. HIV.

Renal safety of tenofovir disoproxil fumarate.

P. Sax, J. Gallant, P. Klotman, 2007, The AIDS reader.

Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV Aged ≥ 65 Years: Week 48 Results of a Phase 3b, Open-Label Trial

R. Haubrich, J. Gallant, L. Vandekerckhove, 2021, Infectious Diseases and Therapy.

A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection: Analysis of Week 96 Results

K. White, P. Sax, A. Zolopa, 2013, Journal of acquired immune deficiency syndromes.

Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results

F. Antunes, J. Gallant, J. Fehr, 2015, Journal of acquired immune deficiency syndromes.

Discontinuation of Tenofovir Disoproxil Fumarate for Presumed Renal Adverse Events in Treatment-Naïve HIV-1 Patients: Meta-analysis of Randomized Clinical Studies

J. Gallant, M. Chonchol, J. Winston, 2014, HIV clinical trials.

Tenofovir disoproxil fumarate

J. Gallant, S. Deresinski, 2003, Reactions Weekly.

Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults

J. Gallant, E. Daar, A. Clarke, 2017, Journal of acquired immune deficiency syndromes.

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

J. Gallant, M. Das, P. Tebas, 2017, Journal of acquired immune deficiency syndromes.

HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients.

D. Fine, J. Gallant, P. Scheel, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV Type 1 RNA Level as a Clinical Indicator of Renal Pathology in

D. Fine, J. Gallant, P. Scheel, 2006 .

Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Joel E Gallant, Edwin DeJesus, Schlomo Staszewski, 2004, JAMA.

Reply to Carr

J. Gallant, M. Shaefer, Michael L. Lim, 2006 .

The Ideal Nucleoside/Nucleotide Backbone

J. Gallant, 2004, Journal of acquired immune deficiency syndromes.

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV: Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

R. Haubrich, J. Gallant, L. Vandekerckhove, 2022, HIV medicine.

Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

J. Nachega, P. Sax, J. Gallant, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of the 1993 revision of the AIDS case definition on the prevalence of AIDS in a clinical setting

Richard D Moore, R. Chaisson, J. Bartlett, 1993, AIDS.

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

Joel E Gallant, Edwin DeJesus, B. Gazzard, 2006, The New England journal of medicine.

Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care

R. Haubrich, A. Go, A. Chokkalingam, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Cavitary pulmonary lesions in patients infected with human immunodeficiency virus.

J. Gallant, A. Ko, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Medical Management of HIV Infection

J. Bartlett, J. Gallant, P. Pham, 1996 .

The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications.

R. Chaisson, J. Gallant, R. Moore, 1998, Chest.

Antiretroviral therapy.

J. Gallant, J E Gallant, 2000, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.

J. Gallant, K. Ghanem, M. Horberg, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of opportunistic disease on survival in patients with HIV infection

R. Chaisson, J. Gallant, J. Keruly, 1998, AIDS.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

Jennifer F Hoy, Michael S Saag, Huldrych F Günthard, 2016, JAMA.

Incidence and Natural History of Cytomegalovirus Disease in Patients With Advanced Human Immune Deficiency Virus Disease Treated With Zidovudine: The Zidovudine Epidemiology Study Group

Richard D Moore, D. Richman, J. Gallant, 1993 .

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance

Joel E Gallant, R. Haubrich, D. Richman, 2002, Antiviral therapy.

The new drugs and how to use them.

J. Gallant, 1999, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

Initial therapy of HIV infection.

J. Gallant, 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Tara L. Kieffer, Joel E Gallant, Charles Flexner, 2005, JAMA.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis

B. Gazzard, J. Gallant, J. Arribas, 2006, Journal of acquired immune deficiency syndromes.

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

K. White, P. Sax, A. Zolopa, 2012, The Lancet.

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs

J. Nachega, J. Gallant, M. Mugavero, 2011, Patient preference and adherence.

Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America.

V. Stone, J. Gallant, J. Currier, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Tenofovir disoproxil fumarate for the treatment of HIV infection

J. Gallant, P. Pham, 2006, Expert opinion on drug metabolism & toxicology.

A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

E. Negredo, J. Gallant, A. Antinori, 2018, AIDS.

Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing

Richard D Moore, J. Gallant, G. Lucas, 2004, AIDS.

Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.

J. Gallant, R. Moore, S. Barnett, 1999, AIDS.

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

Jennifer F Hoy, Amalio Telenti, Michael S Saag, 2014, JAMA.

Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine association of the Infectious Diseases Society of America.

J. Gallant, K. Ghanem, M. Horberg, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Guidelines for the Management of Persons Infected With HIV : 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America

J. Gallant, K. Ghanem, M. Horberg, 2013 .

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis

B. Gazzard, J. Gallant, J. Arribas, 2008, Journal of acquired immune deficiency syndromes.

Antiretroviral drug resistance and resistance testing.

J. Gallant, 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Future of HIV/AIDS Care in Low- and Middle- Income Countries

J. Gallant, C. Hoffmann, L. Mills, 2008 .

Chapter 3 Future of HIV/AIDS Care in Low- and Middle- Income Countries

J. Gallant, C. Hoffmann, L. Mills, 2008 .

A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 144 Results

K. White, P. Sax, A. Zolopa, 2014, Journal of acquired immune deficiency syndromes.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial

D. Podzamczer, K. White, J. Gallant, 2017, The Lancet.

Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.

J. Gallant, D. Berger, Allan E. Rodriguez, 2005, The Journal of infectious diseases.

The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.

Joel E Gallant, J. Gallant, 2006, The AIDS reader.

A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapy

Joel E Gallant, Calvin Cohen, Edwin DeJesus, 2003, AIDS.

When to start antiretroviral therapy: a swinging pendulum?

J. Gallant, 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.

Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users

D. Vlahov, J. Gallant, D. Celentano, 2001, AIDS.

Fatal Granulomatous Amebic Encephalitis Due to Balamuthia mandrillaris in New Mexico: A Case Report

B. Hart, J. Gallant, K. Santacruz, 2014, Open forum infectious diseases.

Host Factors Dictate Control of Viral Replication in two HIV-1 Controller/Chronic Progressor Transmission Pairs

R. Siliciano, J. Blankson, J. Gallant, 2012, Nature Communications.

Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine

J. Gallant, D. Mehrotra, D. Haas, 2000, AIDS.

Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study.

Daniel I. S. Rosenbloom, R. Siliciano, J. Gallant, 2020, The lancet. HIV.

Allogeneic Bone Marrow Transplant for HIV Patients with Hematologic Malignancies with Post-transplant Cyclophosphamide: a Feasibility Study

Daniel I. S. Rosenbloom, R. Siliciano, J. Gallant, 2020 .

Tolerability and Efficacy of PI Versus NNRTI-Based Regimens in Subjects Receiving HAART During Acute or Early HIV Infection

B. Walker, J. Margolick, F. Vaida, 2009, Journal of acquired immune deficiency syndromes.

Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4+ T Cells

Claus O. Wilke, Thomas C. Quinn, Tara L. Kieffer, 2006, Journal of Virology.

The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors

R. Siliciano, J. Blankson, J. Gallant, 2008, AIDS.

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct‐acting antiviral treatment failure

Chih-Wei Lin, Joel Gallant, M. Buti, 2018, Hepatology.

Strategies for long-term success in the treatment of HIV infection.

J. Gallant, J E Gallant, 2000, JAMA.

Absolute CD4 Vs. CD4 Percentage for Predicting the Risk of Opportunistic Illness in HIV Infection

Richard D Moore, J. Gallant, K. Gebo, 2004, Journal of acquired immune deficiency syndromes.

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing

T. F. Rinke de Wit, D. Katzenstein, R. Shafer, 2015, PloS one.

Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.

J. Gallant, 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adherence to antiretroviral regimens in HIV-infected patients: results of a survey among physicians and patients.

J. Gallant, D. Block, Gallant Je, 1998, Journal of the International Association of Physicians in AIDS Care.

Comorbidities among HIV-infected injection drug users in Chennai, India.

J. Gallant, D. Celentano, R. Subbaraman, 2008, The Indian journal of medical research.

Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users

J. Margolick, J. Phair, R. Detels, 2004, AIDS.

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.

Kenneth H Mayer, Ian Sanne, Max Essex, 2014, The Lancet. Infectious diseases.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Risk factors for Kaposi's sarcoma among HHV‐8 seropositive homosexual men with AIDS

J. Goedert, J. Gallant, T. Hendershot, 2005, International journal of cancer.

AVT 8(6) in progress

R. Haubrich, D. Richman, M. Wainberg, 2003 .

Comorbidities Among US Patients With Prevalent HIV Infection—A Trend Analysis

J. Gallant, S. Shreay, P. Hsue, 2017, The Journal of infectious diseases.

Infectious complications of HIV disease.

J. Gallant, 1995, Emergency medicine clinics of North America.

Communications to the EditorThe Effect of Prophylaxis on the Outcome of HIV-Associated Pneumocystis carinii Pneumonia

R. Chaisson, J. Bartlett, J. Gallant, 1996 .

Safety, Tolerability, and Antiretroviral Effects of Ritonavir‐Nelfinavir Combination Therapy Administered for 48 Weeks

J. Gallant, C. Flexner, S. Eshleman, 2000, Journal of acquired immune deficiency syndromes.

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

M. Buti, J. Gallant, T. Pilot‐Matias, 2017 .

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Stability of the latent reservoir for HIV-1 in patients receiving valproic acid.

Richard D Moore, R. Siliciano, J. Margolick, 2007, The Journal of infectious diseases.

Prolonged viral suppression without therapy in an HIV-1 seroconverter following early antiretroviral therapy and daily interleukin-2.

J. Margolick, J. Blankson, J. Gallant, 2010, AIDS.

Short communication: CD4 cell count increases during successful treatment of Graves' disease with methimazole in HIV-infected patients on antiretroviral therapy.

J. Gallant, T. Brown, T. Tsunoda, 2012, AIDS research and human retroviruses.

Respiratory insufficiency from dapsone-induced methemoglobinemia.

J. Gallant, E. Hoehn-Saric, M. D. Smith, 1991, AIDS (London).

Rationale and evidence for human immunodeficiency virus treatment as prevention at the individual and population levels.

J. Gallant, C. Hoffmann, 2014, Infectious disease clinics of North America.

Human Immunodeficiency Virus Medicine

J. Gallant, 2017, The Journal of infectious diseases.

What does the generalist need to know about HIV infection?

J. Gallant, 2010, Advances in chronic kidney disease.

The Ryan White HIV/AIDS Program after the Patient Protection and Affordable Care Act full implementation: a critical review of predictions, evidence, and future directions.

J. Oetzel, J. Gallant, T. Ginossar, 2019, Topics in antiviral medicine.

A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care.

R. Schooley, D. Richman, P. Volberding, 2017, Topics in antiviral medicine.

Approach to the Treatment-experienced patient

J. Gallant, 2005, Infectious disease clinics of North America.

Approach to the treatment-experienced patient.

J. Gallant, 2007, Current HIV/AIDS reports.

Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients

J. Gallant, S. Staszewski, A. Pozniak, 2004 .

Tenofovir disoproxil fumarate (Viread®) for the treatment of HIV infection

J. Gallant, P. Pham, 2003, Expert review of anti-infective therapy.

Bimodal virological response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring

H. Chu, J. Chmiel, A. Muñoz, 2006, Journal of Epidemiology and Community Health.

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

A. Mocroft, J. Gallant, F. Wit, 2022, HIV medicine.

Intramedullary tuberculoma in a patient with HIV infection.

R. Chaisson, J. Gallant, J. McArthur, 1992, AIDS.

High Frequency of Highly Active Antiretroviral Therapy Modifications in Patients with Acute or Early Human Immunodeficiency Virus Infection

J. Margolick, J. Gallant, B. Sabundayo, 2006, Pharmacotherapy.

Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy.

J. Gallant, P. Tarwater, Michelle Parish, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Current status of antiretroviral treatment interruption and intermittent therapy strategies.

J. Gallant, 2002, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

Hepatitis C Virus Testing in Adults Living with HIV: A Need for Improved Screening Efforts

Richard D Moore, Stephen A. Berry, J. Fleishman, 2014, PloS one.

Essential components of effective HIV care: a policy paper of the HIV Medicine Association of the Infectious Diseases Society of America and the Ryan White Medical Providers Coalition.

Joel E Gallant, Adaora A Adimora, Michael Horberg, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052

J. Gallant, J. Eron, M. Hosseinipour, 2017, Journal of acquired immune deficiency syndromes.

Analysis of HIV Integrase Resistance in Black Men Who Have Sex with Men in the United States.

J. Gallant, C. del Rio, S. Shoptaw, 2017, AIDS research and human retroviruses.

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

R. Haubrich, J. Gallant, M. Saag, 2007, AIDS.

Board – – – – — — – — — — — — — — IAS – USA Board of Directors — — — — – — — — — —

R. Shafer, D. Richman, J. Oetzel, 2018 .

MAGELLAN-1, Part 2: Glecaprevir and Pibrentasvir for 12 or 16 Weeks in Patients with Chronic HCV Genotype 1 or 4 and Prior Direct-Acting Antiviral Treatment Failure

M. Buti, J. Gallant, T. Pilot‐Matias, 2017 .

HIV/AIDS: the management of treatment-experienced HIV-infected patients: new drugs and drug combinations.

Joel E Gallant, J. Gallant, L. Wilson, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

High-Risk Behavior and Potential Transmission of Drug-Resistant HIV Among Injection Drug Users

D. Vlahov, S. Gange, J. Gallant, 2004, Journal of acquired immune deficiency syndromes.

A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection

J. Margolick, J. Singer, J. Gallant, 2015, PloS one.

HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy.

R. Siliciano, J. Margolick, J. Gallant, 2012, The Journal of infectious diseases.

Seronegative HIV-1 infection: a review of the literature

J. Blankson, J. Gallant, A. Spivak, 2010, AIDS.

False positive viral load results: recent problems and solutions.

Joel E Gallant, J. Gallant, 2005, The Hopkins HIV report : a bimonthly newsletter for healthcare providers.

Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.

Tara L. Kieffer, Richard D Moore, R. Siliciano, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunologic response among HIV-infected patients enrolled in a graduated cost-recovery programme of antiretroviral therapy delivery in Chennai, India

J. Gallant, S. Solomon, S. Solomon, 2013, The Indian journal of medical research.

Effects of an incentive and education program on return rates for PPD test reading in patients with HIV infection.

R. Chaisson, J. Gallant, J. Keruly, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Track C Epidemiology and Prevention Science

David R. Holtgrave, W. Heneine, Y. Nakamura, 2012, Journal of the International AIDS Society.

IAS-USA Board of Directors

R. Schooley, M. Hirsch, D. Richman, 2011 .

Healthcare utilization and direct costs of non-infectious comorbidities in HIV-infected patients in the USA

J. Gallant, P. Hsue, N. Meyer, 2018, Current medical research and opinion.

Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.

C. Farthing, A. Zolopa, J. Gallant, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV.

R. Haubrich, C. Leen, A. Mocroft, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to efavirenz/emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients

A. Zolopa, J. Gallant, C. Cohen, 2012 .

From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and “augmented” medicine: some considerations on Salvatore Iaconesi’s clinical story

Nicola Luigi Bragazzi, J. Nachega, J. Gallant, 2013, Patient preference and adherence.

Sande's HIV/AIDS Medicine: Medical Management of AIDS 2013: Second Edition

P. Volberding, N. Sewankambo, W. Greene, 2012 .

When to start antiretroviral therapy? NA-ACCORD stimulates the debate.

J. Gallant, 2009, The AIDS reader.

Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial§

J. Gallant, G. Moyle, H. Cao, 2017, Current HIV research.

Risk factors for Kaposi's sarcoma in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group.

R. Chaisson, D. Richman, J. Gallant, 1994, Archives of internal medicine.

Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution.

R. Siliciano, J. Blankson, J. Gallant, 2001, The Journal of infectious diseases.

Impact of the 1993 revision of the CDC case definition on the performance of the WHO and PAHO clinical case definitions for AIDS

R. Chaisson, J. Gallant, T. Quinn, 1993, AIDS.

Human immunodeficiency virus infection and hospital mortality in acute lung injury patients

P. Pronovost, D. Needham, J. Gallant, 2010, Critical care medicine.

Article Commentary: Antiretroviral Therapy in Resource-Limited Settings: Is There Still a Role for Stavudine?

J. Gallant, 2012, Antiviral therapy.

Current perspectives on the nucleoside/nucleotide components of combination antiretroviral therapy.

J. Gallant, 2004, Journal of acquired immune deficiency syndromes.

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel.

P. Volberding, H. Günthard, P. Sax, 2016, JAMA.

The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

R. C. Rose, Todd M. Allen, David S. Rubin, 2010, Science.

Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.

F. Antunes, J. Gallant, J. Fehr, 2013, The Journal of infectious diseases.

Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care

A. Chokkalingam, J. Gallant, E. Price-Haywood, 2020, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.

J. Gallant, R. Grant, I. Frank, 2017, The lancet. HIV.